Latest news

• Eli Lilly scores positive phase 3 results for Emgality in treatment resistant migraine

  Hopes to catch up with rivals in the market. Eli Lilly has announced that its migraine prevention drug Emgality (galcanezumab) has produced positive results in its phase 3 study in patients ... activities. “There is a significant unmet need for

• Lilly claims cluster headache first for CGRP drug Emgality

  Emgality (galcanezumab) has been cleared by the US regulator for the treatment of episodic cluster headache, a migraine-like condition that produces extreme pain and tends to occur in clusters that

• Pricing pressures peg back Lilly’s growth products

  Lilly has other new medicines rolling out to help it manage the Cialis patent cliff, and third-to-market CGRP inhibitor for migraine – Emgality (galcanezumab) - added $14m in the quarter, overtaking

• Novartis and Amgen come to blows over migraine partnership

  It has since been followed by Teva’s Ajovy (fremanezumab) and Eli Lilly’s Emgality (galcanezumab), which have similar dosing requirements.

• Pfizer closes on EU approval of lung cancer drug Vizimpro

  The CHMP also backed Teva’s CGRP inhibitor Ajovy (fremanezumab) for migraine prevention, setting the drug on course to compete with earlier approvals Aimovig (erenumab) from Amgen/Novartis and Emgality (galcanezumab)